Form D · Biotechnology
Nkarta, Inc.
South San Francisco, CA · CIK 0001787400
Offering snapshot reported Sep 6, 2019 · SEC filing
- Reported sold
- $43.9M Offering amount: $115M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 27, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 6, 2019 | Initial | $43,899,296 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-348219
$37,662,583.68 new money; $6,236,712.33 conversion of notes
Source: Form D, filed Sep 6, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tiba Aynechi | Director |
| Fouad Azzam | Director |
| Ali Behbahani | Director |
| Jill Carroll | Director |
| Michael Dybbs | Director |
| Paul Hastings | Director, Executive |
| Matthew Plunkett | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6000 Shoreline Court Suite 102
South San Francisco, CA, 94080
South San Francisco, CA, 94080